Rallybio Corporation

Stage 2 · Advancing · week 33

As of Oct 22, 2026, Rallybio is in Stage 2, the uptrend phase, now in week 33 (since Mar 3, 2026). It closed at $16.40, 4.8% below its 52-week high and above its 200-day average, which is rising.

$16.40

+0.52% today

$87.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is RLYB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 34w

S4 60w

S2 18w

S2 33w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S4 34w → S1 5w → S4 60w → S1 13w → S2 18w → S3 3w → S2 33w current

Total tracked: 166 weeks across 8 stage runs.

RLYB among Biotechnology23rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…23	RLYBRallybio Corporation	Stage 2 · wk 33	98	−2.7%

vs 52W High

-4.8%

$4.33 lo$17.22 hi

4.8% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 33

1w13w26w

Week 33, mature

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

29.9%

200 DMA: $12.62 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.41x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-2.7%

+0.6%

+92.9%

YTD

+190.0%

+266.1%

Scan Membership

Breakout Watch

Latest: 2023-07-21

2 appearances in last 60 days. First seen: 2022-09-09.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 33 · Vol 0.41x

2026-10-21S2

Wk 33 · Vol 1.01x

2026-10-20S2

Wk 33 · Vol 8.83x

2026-10-19S2

Wk 32 · Vol 0.69x

2026-10-16S2

Wk 32 · Vol 3.22x

2026-10-15S2

Wk 32 · Vol 0.26x

2026-10-14S2

Wk 32 · Vol 0.41x

2026-10-13S2

Wk 32 · Vol 0.39x

2026-10-12S2

Wk 31 · Vol 0.45x

2026-10-09S2

Wk 31 · Vol 0.51x

2026-10-08S2

Wk 31 · Vol 0.58x

2026-10-07S2

Wk 31 · Vol 0.53x

Moving averages & range

50 DMA

$16.84

200 DMA

$12.62

52W High

$17.22

52W Low

$4.33

5D Low

$16.28

Resistance levels (recent highs)

20d High

$17.22

60d High

$17.22

120d High

$17.22

250d High

$17.22

Next resistance

+5.0%

to 20d High

P/E (TTM)

2.0

Forward -3.0

ROE

+64.9%

Profit margin +7051.2%

Dividend Yield

0.00%

P/B 0.9

Rallybio: quick answers

What stage is Rallybio in?

As of Oct 22, 2026, Rallybio (RLYB) is in Stage 2, the uptrend phase. It entered Stage 2 on Mar 3, 2026 and is in week 33. What the four stages mean

Is Rallybio in an uptrend?

Yes. Rallybio is in a Stage 2 uptrend. It trades 29.9% above its 200-day average, which is rising.

How far is Rallybio from its 52-week high?

Rallybio closed at $16.40 on Oct 22, 2026, 4.8% below its 52-week high of $17.22. Its 52-week low is $4.33.

How has Rallybio performed over the past year?

As of Oct 22, 2026, Rallybio is up 266.1% over the past year and up 190.0% so far in 2026.

Which sector and industry is Rallybio in?

Rallybio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.